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Needle exchange programs for the
prevention of hepatitis C virus infection in
people who inject drugs: a systematic
review with meta-analysis
Stephen M. Davis1* , Shay Daily2, Alfgeir L. Kristjansson2, George A. Kelley3, Keith Zullig2, Adam Baus2,
Danielle Davidov1,2 and Melanie Fisher4
Abstract
Background: Previous research on the effectiveness of needle exchange programs (NEP) in preventing hepatitis C
virus (HCV) in people who inject drugs (PWID) has shown mixed findings. The purpose of this study was to use the
meta-analytic approach to examine the association between NEP use and HCV prevention in PWIDs.
Methods: Study inclusion criteria were (1) observational studies, (2) PWIDs, (3) NEP use, (4) HCV status ascertained
by serological testing, (5) studies published in any language since January 1, 1989, and (6) data available for measures
of association. Studies were located by searching four electronic databases and cross-referencing. Study quality was
assessed using the Newcastle Ottawa (NOS) scale. A ratio measure of association was calculated for each result from
cohort or case–control studies and pooled using a random effects model. Odds ratio (OR) and hazard ratio (HR)
models were analyzed separately. Results were considered statistically significant if the 95% confidence interval
(CI) did not cross 1. Heterogeneity was estimated using Q and I2 with alpha values for Q ≤ 0.10 considered
statistically significant.
Results: Of the 555 citations reviewed, 6 studies containing 2437 participants were included. Studies had an
average NOS score of 7 out of 9 (77.8%) stars. Concerns over participant representativeness, unclear adjustments
for confounders, and bias from participant nonresponse and loss to follow-up were noted. Results were mixed
with the odds ratio model indicating no consistent association (OR, 0.51, 95% CI, 0.05–5.15), and the hazard ratio
model indicating a harmful effect (HR, 2.05, 95% CI, 1.39–3.03). Substantial heterogeneity (p ≤ 0.10) and moderate
to large inconsistency (I2 ≥ 66%) were observed for both models.
Conclusions: The impact of NEPs on HCV prevention in PWIDs remains unclear. There is a need for well-designed
research studies employing standardized criteria and measurements to clarify this issue.
Trial registration: PROSPERO CRD42016035315
Keywords: Needle exchange program, Meta-analysis, Systematic review, Hepatitis C, Injection drug use, Opioids,
Heroin, Pain killers, Pain
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Background
Rationale
Globally, over 184 million people (>2.8% of the world’s
population) have been infected with the hepatitis C virus
(HCV) [1]. HCV is a blood-borne virus that infects the
liver. Approximately 75% of acute HCV infections be-
come chronic [2]. Chronic HCV infection significantly
increases the risk of liver disease, especially cirrhosis and
liver cancer [1–7]. A majority of the 350,000 deaths attrib-
uted to HCV infection each year are caused by cirrhosis
and hepatocellular carcinoma [7]. In most countries, the
annual incidence of HCV infection has peaked with the
exception of Russia where new cases are still increasing
[1]. However, a troublesome pattern of new HCV cases
observed in the USA suggests another or recurrent public
health epidemic [1, 2, 8, 9].
The incidence of HCV in the USA declined from
2000–2005 and plateaued during 2005–2010 [8]. There-
after, the number of reported acute cases increased sig-
nificantly with a 2.6-fold increase observed between
2010 and 2014 [8]. Collectively, a 364% increase in HCV
cases among persons aged ≤30 years was observed in
Central Appalachia (Kentucky, Tennessee, Virginia, and
West Virginia) between 2006 and 2012 [10]. As a result,
the USA has set a goal of reducing new hepatitis C in-
fections from 0.28 cases per 100,000 to 0.25 cases per
100,000 (Healthy People 2020 Objective IID-26) [11].
HCV-infected patients consume a large proportion of
healthcare resources in the USA. Between 2001 and 2010,
HCV-infected individuals accounted for almost 3 million
outpatient, inpatient, and emergency department visits in
the USA [6]. Estimated healthcare costs associated with
the treatment and care of chronic HCV was $6.5 billion in
2011 and is expected to peak at $9.1 billion in 2024 [3].
Although HCV can be transmitted in several ways, the
primary mode of HCV exposure is percutaneous with
injection drug use remaining the largest risk factor for
HCV infection [2, 3, 8, 9, 12–18]. People who inject
drugs (PWID) account for approximately 60–70% of the
incidence of new HCV infections in the USA and many
other countries [2]. Globally, it is estimated there are 10
million PWIDs that have HCV infection [18]. The preva-
lence of HCV infection in PWIDs ranges between 40
and 90% and has been observed to be as high as 98%
[10]. Recent evidence from the USA has shown that
many of these PWIDs are White [2, 9, 14, 15] and young
(<35) [2, 8, 9, 14, 15] and have a history of prescription drug
use and abuse, especially prescription opiates [2, 13–15].
Furthermore, two recent studies suggest that HCV-
infected PWIDs are more likely to reside in non-urban
areas [14, 15].
Harm reduction interventions aim to reduce individual
and societal harms stemming from drug use by targeting
risky behaviors and risky settings [19]. A needle exchange
program (NEP) is one popular harm reduction interven-
tion that seeks to reduce risky settings. NEPs provide
clean needles in exchange for used needles to minimize
the reuse of needles contaminated with infectious disease
during drug injection [19]. Many NEPs also provide other
prevention materials and services such as additional sterile
injecting supplies (e.g., cotton and alcohol swabs), wound
care and safe injecting practices education, and linkage
and referral to substance treatment programs for those
PWIDs ready to quit injecting [20]. However, the evidence
for the effectiveness of NEPs in preventing HCV among
PWIDs is mixed [21]. For example, a systematic review
with meta-analysis of several interventions, including
NEPs, to prevent HCV infection in PWIDs observed an
increased risk of HCV seroconversion associated with
NEP use (RR 1.62, 95% CI, 1.04–2.52), although sub-
stantial heterogeneity was observed (Q = 32.3; P < 0.01;
I2 = 81%) [12]. Furthermore, this systematic review only
included studies published through April 2010, and se-
lected studies were limited to the injection of illegal
drugs (heroin, amphetamine, and cocaine) by PWIDs.
Thus, studies describing the injection of prescription
opioids were not considered for inclusion in the analysis.
In another study, a review of reviews by MacArthur et al.
[21] concluded that there was insufficient evidence to sup-
port or discount the effectiveness of NEPs for the preven-
tion of HCV in PWIDs. A more recent systematic review
of needle/syringe programs for the reduction of HCV in-
fection among PWIDs by Abdul-Quader et al. [22] found
that 6 of the 15 included studies (40%) reported decreases
in HCV infection. However, included studies only exam-
ined structural and population level interventions, as op-
posed to the association between individual use of NEPs
and HCV infection. Finally, a recently published system-
atic review with meta-analysis by Sawangiit et al. [23] ex-
amined the effectiveness of pharmacy-based NEPs for
PWIDs. However, in addition to specifically focusing on
pharmacy-based NEPs, which may not always exchange
needles [24], this study only examined the impact of these
programs on the prevalence of HCV versus the prevention
of new infections (incidence). To the best of the authors’
knowledge, no other systematic reviews with or without
meta-analyses of the effectiveness of NEPs in preventing
HCV in PWIDs currently exist. Therefore, the primary
objective of this study was to conduct a systematic review
with meta-analysis to examine the association between
NEPs and the prevention of HCV in PWIDs.
Methods
General procedure
The conduct and reporting of this study followed the
recommended guidelines from the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis
(PRISMA) statement [25]. This systematic review with
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meta-analysis is registered in the PROSPERO trial
registry (CRD42016035315).
Study eligibility criteria
The a priori inclusion criteria for this systematic review
with meta-analysis were as follows: (1) observational
studies, (2) PWIDs, (3) NEP use, (4) HCV status ascer-
tained by serological testing (saliva or serum), (5) studies
published in any language after January 1, 1989, and (6)
data available or calculable for measures of association
between participation in a NEP and HCV infection.
Studies were excluded based on inappropriate study
design, population, intervention, or lack of available in-
formation to calculate a measure of association between
program participation and HCV infection.
Although randomized controlled trials are considered
the highest level of evidence for examining the effect of
an intervention on a health outcome, [26] it was antici-
pated that no such trials would be found given that it
would be highly unethical (violation of the ethical
principle of beneficence) to randomize subjects away
from a potentially beneficial treatment (i.e., needle ex-
change). Therefore, the focus of the review was on ob-
servational studies.
An a priori decision was made to exclude studies that
reported the use of supervised injection facilities (SIFs).
The rationale for this exclusion was based on the obser-
vation that while SIFs provide a safe environment for
drug users to inject drugs, such facilities may not always
provide (exchange) clean needles [27]. Additionally,
studies describing the distribution of clean syringes from
pharmacies were also excluded because such programs
typically involve the sale of clean syringes with or with-
out a prescription but may not involve the exchange of
clean needles for dirty needles [24]. HCV status ascer-
tained by serological testing was chosen as the primary
outcome because previous research has demonstrated
low sensitivity when HCV status is self-reported by
PWIDs [28]. The year 1989 was chosen as a starting
point for the search because this was the year that the
HCV antibody was identified, and thus, enabled sero-
logical testing to detect the virus [29]. Based on the rec-
ommendations by van Driel et al. [30], no searches for
unpublished works such as dissertations and conference
abstracts or other unpublished reports were conducted.
Data sources
The following databases were searched between July 18,
2016, and August 24, 2016: (1) PubMed, (2) Scopus, (3)
Web of Science, and (4) CINAHL. The search strategy
and terms were based on the work of the HCV synthesis
project [29] and was modified to include specific search
terms related to NEP that were used by Abdul-Quader
et al. [22] in their systematic review of population level
outcomes following the implementation of NEP. Addi-
tionally, the term “people who inject drugs” was included
in the search given the observation by the authors that
this term has been commonly used to refer to injection
drug users in more recent research literature. Although
there was slight variation in the specific search format
between databases, the following search terms and
combinations were used: (hepatitis C OR HCV) AND
(intravenous drug abuse OR intravenous drug use OR
drug misuse OR drug addict OR injecting drug use OR
drug abuse OR people who inject drugs OR PWID OR
PWID) AND (prevention OR risk factor OR epidemi-
ology OR prevalence OR incidence OR seroprevalence
OR seroincidence OR seroconversion OR genotype OR
coinfect*) AND (needle exchange OR needle exchange
program OR syringe exchange program OR syringe access
program) AND (“1989/01/01” [Date - Publication] : “3000”
[Date - Publication]). Search strategy examples for the four
databases searched are included in Additional file 1. In
addition to database searches, cross-referencing from
retrieved studies and reviews was also conducted. After
identifying the final number of studies to be included,
the number needed to read (NNR) was calculated by
taking the inverse of the precision, which was defined
as the number of included studies divided by the total
number of studies screened after removal of duplicates
[31]. All studies identified during the search were
stored in EndNote® version 7.4 [32].
Study selection
Two researchers (SMD and SD) independently reviewed
studies for selection and abstracted data from eligible
studies with discrepancies resolved by consensus and dis-
cussion with a third researcher (GK), if needed. Duplicate
studies were discovered by using the “Find Duplicates”
tool in EndNote® 7.4 [32] and by manual examination.
After removal of duplicate studies, abstracts of all studies
were reviewed and the full text of studies appearing to
meet the inclusion criteria were obtained and reviewed.
Studies that met all of the inclusion criteria were selected.
The authors were not blinded to journal titles and study
authors and their associated institutions during the review.
Reasons for exclusion from further review were coded as
one or more of the following: (1) inappropriate population
(i.e., not PWIDs), (2) inappropriate intervention (i.e.,
not a NEP), (3) inappropriate comparison (i.e., no com-
parison to non-exchange users), (4) inappropriate out-
come (i.e., self-reported HCV status), and (5) lack of
data to enable calculations of the association between
program use and HCV infection.
Data abstraction
A codebook containing 85 items was developed a priori
using Microsoft Excel 2013®, [33] and is included in
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Additional file 2. The major categories of variables coded
by the authors were based upon the HCV Synthesis
Project [29] and included (1) study characteristics (author,
journal, year, funding status, design, inclusion criteria,
recruitment method, recruitment locations, method of
determining PWID status, specimen type, and HCV test
method), (2) participant characteristics (age, gender,
ethnicity, duration of drug use, type of drug used, fre-
quency of use), and (3) outcome characteristics (preva-
lence, incidence, number of person years, sample size, and
variables adjusted for, if applicable). The primary outcome
of this study, established a priori, was the association
between HCV seroconversion and use of a NEP.
Risk of bias assessment
The risk of bias in selected studies was assessed using
the Newcastle-Ottawa Quality Assessment Scale (NOS)
[34]. Consistent with previous research, no study was ex-
cluded based on the risk of bias assessment [35].
Statistical analysis
The a priori plan was to conduct an aggregate data
meta-analysis with the study as the unit of analysis.
Calculation of effect sizes
The primary outcome for this study was the association
between HCV seroconversion and participation in a
NEP observed in either cohort studies that follow sero-
negative individuals over time to monitor seroconversion
or case–control studies. This outcome was calculated as
the log odds ratio (OR) or the log hazard ratio (HR).
Because hazard ratios include a time component, ORs
and HRs were analyzed separately.
Where possible, published ratios (OR or HR) and con-
fidence limits from individual studies were used to cal-
culate the log ratios and corresponding logs of the
standard errors. If associations in individual studies were
not presented in ratios, only log odds ratios were calcu-
lated using the reported number of HCV infections and
the total number of participants in each group (NEP
users and non-users). Missing log hazard ratios were not
calculated due to the unavailability of time data. If an
exact p value was reported instead of a confidence inter-
val (CI), the standard error was calculated using the
following formula [26]: log(OR)/z. If reported, adjusted
effects were used as the primary outcome under the as-
sumption that such effects have been adjusted for poten-
tial bias in the observed association between NEP
participation and HCV infection. For ease of interpret-
ation, log ratios were converted back to odds ratios and
hazard ratios after analysis.
Pooling estimates
Effect size estimates from individual studies were pooled
using a random effects model [36]. Between-study het-
erogeneity was evaluated using the Q statistic, and the
percentage of variation in effect estimates due to hetero-
geneity was assessed using the I2 statistic [37]. Based on
current recommendations, heterogeneity was considered
to be substantial if the p value for the observed Q statis-
tic was ≤0.10 [26]. The amount of heterogeneity present
(as assessed by I2 values) was interpreted according to
the following categories: <25% (“very low”); 25 to <50%
(“low”); 50 to <75% (“moderate”); and 75% or greater
(“large”) [37]. Effect sizes were calculated after each
study was removed from the model in order to assess
the influence of each study on the overall results. In
addition, cumulative meta-analysis, ranked by year of
publication, was conducted to examine the accrued re-
sults over time. Ninety-five percent confidence intervals
that did not cross 1 were considered to be statistically
significant with values below one indicative of a decrease
in the odds or risk of HCV seroconversion (evidence of
a preventative or positive effect). Values significantly
above one were considered to indicate a harmful or
negative effect. Values that crossed 1 were considered to
indicate no effect from NEP participation on the preven-
tion of HCV infection.
An a priori plan was made to assess small-study effects
(publication bias, etc.) using funnel plots and Egger’s re-
gression intercept test (one-tailed). However, we were
unable to conduct these analyses because we did not
have at least 10 effect sizes, the minimum sample size
recommended by Sterne et al. [38]. Similarly, a priori
plans to conduct a mixed-effects meta-regression to
examine potential covariates and a moderator analysis to
examine potential differential study effects from different
study designs (e.g., cohort and case study) were not con-
ducted due to insufficient sample sizes (<10 effects) [26].
All analyses were carried out using Comprehensive
Meta-Analysis (version 3.0) [39].
Results
Study characteristics
Overall, of the 555 references examined, 6 studies,
[40–45] containing data from 2437 PWIDs, were in-
cluded in the final review and analysis. One study [46]
was identified that contained estimates based on data
from the same sample of PWIDs collected in the same
location during the same time periods as those in-
cluded in another larger and more recent study that
was selected for inclusion [42]. Therefore, this study
was eliminated from analysis given that these data would
have violated the statistical requirement of independence
of effect size estimates. The precision of the search was
1% (6/555), and the NNR was 100. Figure 1 diagrams the
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search process and includes reasons for the exclusion of
various studies from the final analysis. Table 1 lists the
general study characteristics. Half of the studies were con-
ducted in the USA [40–42], followed by two conducted in
Canada [43, 44], and one conducted in Afghanistan [45].
Without exception, all studies were conducted in densely
populated urban locations. All studies were published in
the English language. There was one case–control study
[40] and five cohort studies [41–45].
Participant characteristics
All studies enrolled PWIDs who self-reported injections.
However, time since last injection prior to enrollment
varied between studies with two studies enrolling partici-
pants that had injected in the previous month [43, 45],
one study enrolling those that injected in the previous
6 months [44], one study enrolling those that had injected
in the past year [41], one study containing a mix of partici-
pants who injected in the previous 6 months and 1 year
[42], and one study not specifying any length of prior
injection [40].
Participants were enrolled in a variety of settings ran-
ging from syringe exchange programs, [44] harm reduc-
tion programs which provided motivational counseling,
washing facilities, medical care, and infectious diseases
testing in addition to syringe distribution [45], emer-
gency rooms [40], county health departments [40], jails
[41], streets [41–43], social service agencies [41], and
areas of known drug user congregation [45].
A variety of sampling schemes were described including
respondent driven [42], criterion [40], convenience [44],
random [41], and a variant of time-location sampling [45].
One study did not describe the sampling strategy [43].
Study participants were recruited over two decades with
the oldest study recruiting during 1991 to 1993 [40] and
the most recent study enrolling participants between June
2007 and March 2009 [45].
Of the 2437 PWIDs, 941 reported participation in a nee-
dle exchange program (“NEP users”) and 946 participants
did not report using a needle exchange (“non-users”). Two
studies did not report needle exchange participation for
the number of participants who were HCV seronegative at
Fig. 1 Flow diagram for the selection of studies. *Number of reasons exceeded the number of studies because some studies were excluded for
more than one reason
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baseline [44, 45]. With the exception of one study that
only enrolled males [45], all other studies enrolled both
genders. The percentage of male participants in these
studies ranged from a low of 42.3% [40] to a high of 73%
[44] with an average of 62%. Participants in all studies
were generally young (<40 years). However, reporting of
age was variable with the average given in one study
(31.8 years [44]), medians in two studies (28 years [43, 45]),
and age categories in the remaining three studies [40–42].
In these latter three studies, the proportion of all partici-
pants less than 34 years of age was at least 65%.
There was a wide variability in the reporting of partici-
pant race and/or ethnicity with two studies [44, 45] not
reporting any race and/or ethnicity. Of the five studies
reporting race and/or ethnicity, “White” race was the
most frequently reported by participants, ranging from a
low of 49% [42] to a high of 85% [40].
The types of drugs injected varied between studies.
The most frequent drugs injected, self-reported by
participants in each study, included heroin [41, 43] and
cocaine [44]. Three studies [40, 42, 45] did not report a
specific type of drug.
Length of time injecting was also widely variable
between studies. Three studies reported median injecting
durations of 2 years [42, 45] and 7 years [43]. Another
two studies partitioned injecting duration into categories.
Hagan et al. [40] reported the following categories: HCV
positive cases: <5 years (n = 7, 35%), 5+ years (n = 13,
65%); HCV negative controls: <5 years (n = 6, 23.1%),
5+ years (n = 20, 76.9%). Hagan et al. [41] reported
the following categories (years): ≤1 (n = 57, 13%), 1.1
to 2.0 (n = 76, 16%), 2.1–5.0 (n = 144, 32%), 5.1–10.0
(n = 84, 19%), >10.0 (n = 93, 20%). Roy et al. [44] re-
ported an average of 10 years of injecting.
Half of the studies did not report any information re-
lated to the frequency of injections [40, 44, 45]. In the
three studies reporting injection frequency [41–43], the
proportion of participants injecting at least once a day
averaged 51.03%.
Intervention characteristics
Participation in a NEP was assessed by self-report in all
six studies. The frequency of participation varied between
studies due to heterogeneity in the presentation of results.
Two studies reported ever (versus never) using a NEP
[40, 41]. Two studies reported NEP use in the last
3 months [42, 45]. Three studies reported NEP use in
the last 6 months [42–44], with Patrick et al. [43] re-
quiring NEP attendance at least once per week in the
past 6 months.
Risk of bias assessment
Risk of bias assessment results are shown in Table 2. In-
dividual study scores ranged from 5–8 stars, which
represented 55–89% of the total number of stars that
can be awarded (9 stars). The five cohort design stud-
ies [41–45] averaged 7 stars with the lone case–con-
trol study [40] receiving 6 stars.
Four of the six studies [41–43, 45] received the max-
imum number of stars (4) in the selection category. Con-
cerns over the representativeness of participants resulted
in the deduction of one star from this category in the
remaining two studies [40, 44]. All but two of the studies
received the maximum number of stars (2) in the compar-
ability category. Patrick et al. [43] and Roy et al. [45] each
received only one star in this category because adjustments
for potential confounders were unclear. No studies re-
ceived the maximum number of three stars in the assess-
ment of the exposure (case–control) or outcome (cohort)
category. Potential bias from participant nonresponse and
loss to follow-up was a primary weakness for all studies.
Primary outcome
Study outcomes are shown in Table 3. Four studies
reported (or had data enabling calculation of) hazard ra-
tios [41, 43–45], with two studies reporting odds ratios
[40, 42]. Three studies [40, 42, 43] adjusted effect esti-
mates for potential confounders. Overall, findings were
mixed. A statistically significant harmful effect from par-
ticipation in NEPs was observed when the four studies
that reported hazard ratios were combined (pooled HR,
2.05, 95% CI, 1.39–3.03, Fig. 2a). However, significant
heterogeneity and moderate inconsistency were observed
(Q = 9.03; p = 0.029; I2 = 66.8%). This finding was not in-
fluenced by the deletion of any study from the model
once (Fig. 2b) and remained consistent over time
(Fig. 2c), with all cumulative results yielding confidence
intervals that did not cross 1. In contrast, there was no
significant association between the odds of HCV sero-
conversion and participation in a NEP when the two
studies that reported odds ratios were combined (pooled
OR, 0.51, 95% CI, 0.05–5.15, Fig. 3), although both sig-
nificant heterogeneity and large inconsistency between
studies were observed (Q = 8.66; p = 0.003; I2 = 88.4%).
Influence analysis and cumulative meta-analysis were
not conducted on the odds ratio model given the inclu-
sion of only two studies.
Table 2 New-Castle Ottawa Scale Ratings
Study Selection Comparability Exposure/Outcome
Hagan 1995 [40] ★★★ ★★ ★
Hagan 2004 [41] ★★★★ ★★ ★★
Holtzman 2009 [42] ★★★★ ★★ ★
Patrick 2001 [43] ★★★★ ★ ★★
Roy 2007 [44] ★★★ ★ ★
Todd 2015 [45] ★★★★ ★★ ★★
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Discussion
The primary purpose of this systematic review with
meta-analysis was to assess the potential effect of NEP
on the prevention of HCV infection in PWIDs. The
overall findings were mixed and suggest that NEP could
either increase the risk of HCV infection in PWIDs or
have no effect. This interpretation is supported by (1)
pooled results from studies reporting a hazard ratio that
indicate a harmful effect (pooled HR, 2.05, 95% CI,
1.39–3.03), (2) pooled results from studies examining
the odds of infection that do not indicate either a prevent-
ive benefit or harmful effect (pooled OR, 0.51, 95% CI,
0.05–5.15), and (3) substantial heterogeneity (p ≤ 0.10)
and moderate (I2 = 67%) to high (I2 = 88%) inconsistency
observed for both models. These mixed findings are con-
sistent with previous research.
A review of reviews without meta-analysis by MacArthur
et al. [21] of interventions to prevent HCV in PWIDs iden-
tified 17 studies with mixed results (9 positive, 2 negative,
and 6 no effect) leading to the conclusion that there was
insufficient evidence to either support or discount the ef-
fectiveness of NEP for preventing HCV.
Hagan et al. [12] conducted a systematic review with
meta-analysis of the effectiveness of interventions, in-
cluding NEP, on the prevention of HCV. Similar to the
results from our hazard ratio model, this meta-analysis
observed a 62% increase in the risk of HCV seroconver-
sion from participation in syringe access programs (RR,
1.62, 95% CI, 1.04–2.52) with substantial heterogeneity
and large inconsistency (Q = 32.3, I2 = 81%). Included
studies contained a mixture of no effect (three studies),
positive (one study), and harmful (three studies) results.
Five of these seven studies were included in our meta-
analysis. A single-site study by Thorpe et al. [46] which
observed no effect (HR, 1.29, 95% CI, 0.6–2.79) from
NEP participation on HCV infection contained data that
were also included in the Holtzman et al. [42] multi-site
study. Therefore, we excluded this study from the final
model to maintain the criterion of independence of
effect sizes. Despite extensive searching and multiple
electronic and personal queries, we were unable to lo-
cate a governmental report by Lamonthe et al. [47] for
review and possible inclusion in our systematic review
with meta-analysis. Hagan et al. [12] reported that this
study demonstrated a harmful effect (HR, 2.24, 95% CI,
1.01–4.98). The current review included one additional
cohort study [45], published in 2015, that observed a
harmful effect.
A recently published systematic review with meta-
analysis of pharmacy-based NEP demonstrated a 74% re-
duction in the odds of HCV infection (OR = 0.26, 95%
CI, 0.18, 0.38) associated with pharmacy-based NEP par-
ticipation [23]. However, the authors cautioned that this
finding was unclear due to the very small number of
included studies (n = 2) and significant bias concerns.
Observed heterogeneity in the study population, and
variability in defining the intervention and outcomes re-
ported, further precluded the ability to draw definitive
conclusions between HCV infection and pharmacy-
based NEP participation. This observation is consistent
with the current review. Indeed, the substantial hetero-
geneity and large inconsistency observed in both the
current study and the previous meta-analyses may be
related to important between-study differences in the
population enrolled, intervention examined, outcome
assessed, and type of study design (and associated statis-
tical analyses).
Variable populations
All studies included in the current review, with the not-
able exception of Todd et al. [45], enrolled a mix of
genders that were largely under the age of 40 and White.
However, all studies had slightly different age require-
ments with some studies enrolling PWIDs as young as
14 years [41] and 15 years [43] compared to other
studies that did not report a limit on age [40, 44], only
enrolled adults (≥18 years [45]), or had varying age range
requirements (e.g., 18–30 and 18–40) [42]. Furthermore,
Table 3 Study outcomes and adjustments
95% CI
Study Outcome Adjusted Adjustments Estimate Lower Upper p
Hagan 1995 [40] Odds ratio y Sex, race/ethnicity, duration of
drug injecting
0.14 0.03 0.62
Hagan 2004 [41] Hazard ratio n 1.40 0.90 1.90
Holtzman 2009 [42] Odds ratio y Sex, age in years, race/ethnicity,
education, source of income, site,
study time period, injection risk
behaviors, and HIV serostatus
1.49 0.96 2.29
Patrick 2001 [43] Hazard ratio y Not described 2.56 1.37 4.79
Roy 2007 [44] hazard ratio n 3.02 0.18
Todd 2015 [45] Hazard ratio n 1.72 1.07 2.76
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there were a variety of settings in which PWIDs were re-
cruited over an almost 20-year timeframe. However, with
the exception of Todd et al. [45], all included studies
were conducted in North America. Importantly, no
studies took place in the rural, Central Appalachian re-
gion of the USA, an area that is in the midst of a hepatitis
C epidemic that is directly related to increasing prescrip-
tion opioid abuse and injection of heroin [48, 49].
Additionally, injection use appeared to be entirely self-
reported in all studies, and there were variances in the
length of time from last injection criterion between
studies, with some studies enrolling individuals who re-
ported ever injecting [40] to other studies only enrolling
individuals who injected at least once in the previous
month [43, 45].
Variable interventions
Participation in NEP was self-reported in all studies.
However, the frequency of attendance was highly vari-
able between studies, ranging from questions querying
Fig. 2 a Forest plot for the risk of hepatitis C infection among needle exchange program participants. The black squares represent the risk of
hepatitis C infection observed in each study with the 95% confidence intervals represented by the lines on each side of the squares. The diamond
represents the pooled risk of hepatitis C infection with the 95% confidence interval indicated by the left and right extremes of the diamond. b Influence
analysis for the risk of hepatitis C infection among needle exchange program participants. Influence analysis for point estimate changes in the risk of
hepatitis C infection with each individual study deleted from the model once. c Cumulative meta-analysis for the risk of hepatitis C infection
among needle exchange program participants. The results of each corresponding study, ordered by year of publication from oldest to newest,
are pooled with all studies preceding it
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whether or not a program had ever been used [40, 41] to
NEP attendance at least once per week in the previous
6 months [43]. No pattern between study findings and
reported frequency of attendance was observed.
Variable outcomes
Although all studies included a serological measure of
HCV, one study demonstrating a harmful effect used
saliva measurements [44], which may vary in accuracy
compared to serum tests. Additionally, the particular
assay used in the serum measurements was variable with
some studies using second-generation assays and others
using third-generation assays.
Variable study designs and analyses
The particular type of outcome assessed was directly re-
lated to variability in study design and the associated
outcomes. In the current review, cohort studies that in-
corporated a time component into the analysis and re-
ported hazard ratios, demonstrated a significant increase
in the risk of HCV infection for NEP users; whereas, the
lone case–control study [40] that reported an odds ratio
demonstrated a highly significant preventative effect
from NEP use. In contrast, Holtzman et al. [42] analyzed
data from a combination of observational cohort studies
and a subset of data from a randomized behavioral inter-
vention, and reported an odds ratio that demonstrated
no significant effect from NEP participation on the
prevention of HCV. These differences in outcomes pre-
cluded the ability to combine all effect sizes into one
model and instead resulted in two models with different
interpretations. Although this plan differs from the com-
bined model presented by Hagan et al. [12], we made
this decision a priori based on the rationale that odds ra-
tios and hazard ratios are two fundamentally different
measures, given that the latter incorporates a time com-
ponent (i.e., time-to-event data). Although not recom-
mended, time-to-event data can sometimes be analyzed
as dichotomous data that yield odds ratios [26]. How-
ever, such an analysis requires that the status (e.g., ser-
ostatus) of all patients be known at a fixed time point
(i.e., 12 months) [26], which was not reported in all
studies included in our hazard ratio model. Further
complicating matters is that some studies made adjust-
ments to the overall reported main outcome whereas
other studies only reported unadjusted results. Among
those studies that made adjustments, different potential
confounders were controlled for likely leading to
additional heterogeneity between studies.
In a recent review of reviews, MacArthur et al. [21] re-
ported a similar pattern of variability in findings by study
design. Of the 17 studies examining the impact of NEP on
the prevention of HCV, nine studies (one case–control
study, six cross-sectional studies, and two ecological
studies) demonstrated a positive (or preventative) effect
from NEP use. In contrast, two cohort studies demon-
strated a negative (or harmful) effect. The remaining six
studies demonstrated no association and were evenly split
between three cohort studies and three cross-sectional
studies.
While we made an a priori decision to exclude cross-
sectional studies in our meta-analysis due to the fact that
such designs can only assess associations between NEP
participation and HCV infection, the current review
identified five cross-sectional studies that met all other
inclusion criteria [50–54]. Results from these studies
were mixed with one study finding no effect from NEP
participation (OR, 1.54, 95% CI, 0.73–3.24) [50], one
study finding a preventative effect (OR, 0.59, 95% CI,
0.43–0.77) [53], and three studies demonstrating a
harmful effect (OR, 2.17, 95% CI, 1.38–3.40 [51]; OR,
2.1, 95% CI, 1.54–2.89 [52]; OR, 2.54, 95% CI, 1.36–4.74
[54]). Similar to the findings from the current review,
not all studies adjusted odds ratios for confounding, and
the various adjustments made were not uniform between
studies. Qualitative heterogeneity in the measurement of
Fig. 3 Forest plot for the odds of hepatitis C infection among needle exchange program participants. The black squares represent the odds of
hepatitis C infection observed in each study with the 95% confidence intervals represented by the lines on each side of the squares. The diamond
represents the pooled odds of hepatitis C infection with the 95% confidence interval indicated by the left and right extremes of the diamond
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both the exposure (NEP use) and outcome (HCV infec-
tion) were also reported. Finally, Turner et al. [55] con-
ducted a meta-analysis of cross-sectional and cohort
studies conducted in the UK and observed no effect
from NEP participation on HCV incidence (ES, 0.58,
95% CI, 0.30–1.15). Interestingly, and in contrast to all
other studies, no inconsistency (I2 = 0.0%) was reported
in the model. The two cohort studies included in this
model did not contain data that would allow calculation
of the association between NEP use and HCV infection
(inclusion criteria #6).
HIV studies
The heterogeneity observed in this systematic review
with meta-analysis is not limited to studies examining
the effectiveness of NEP for the prevention of HCV. A
recent systematic review with meta-analysis by Aspinall
et al. [56] examining the influence of NEP on prevention
of HIV observed large inconsistency (I2 = 75.7%) between
the 12 included studies (10 cohort, 1 cross-sectional, and
1 case–control). Although a preventative effect from NEP
exposure was suggested, the upper bound of the confi-
dence interval slightly crossed 1 (pooled effect size, 0.66,
95% CI 0.42–1.01). When higher-quality studies, as graded
by the Newcastle-Ottawa Scale, were combined, a sig-
nificant preventative effect was observed (0.42, 95% CI,
0.22–0.81), although large inconsistency (I2 = 80%)
remained. Similar to the current review, variability in
study populations, measurements of the intervention
and exposure, and statistical analyses, likely contributed
to significant heterogeneity in the models. In particular,
the authors graded the overall quality of the evidence
as “low” due to considerable limitations observed in the
primary studies. Potential confounding of results from
historical threats to internal validity, especially the
introduction of antiretroviral medicines that minimize
transmissible viral load and sexual health promotion
programs, was a noted concern. Additionally, the statis-
tical power to detect a significant result was low due to
the fact that HIV seroconversions were a relatively rare
event, which is also a problem in studies examining the
role of NEP in preventing HCV seroconversion. Of
note, many of the primary studies only examined HIV
incidence as a secondary outcome.
Implications for research and practice
The previously discussed qualitative between-study dif-
ferences that may be contributing to the substantial
statistical heterogeneity and large inconsistency raise
several important implications for future research. More
specifically, there is a need for well-designed cohort
studies that follow seronegative individuals forward in
time to track potential seroconversion. It is suggested
that these studies seek standardization of interventions
and outcomes in the following areas: (1) inclusion criteria,
(2) injection use timeframe, (3) definition and measure-
ment of NEP use, (4) outcome assessment, and (5) statis-
tical analysis plan.
With regard to suggestion 3, more objective measures
of program attendance are recommended, but may be
difficult to implement in practice. In particular, some
needle exchanges do not require identification to obtain
needles [57], which precludes the ability to objectively track
program attendance. Alternatively, a randomly assigned
identification number could be implemented to track both
program attendance and any potential seroconversion.
With regard to suggestion 5, given the fact that a re-
cent meta-analysis found a 94% increased risk of HCV
seroconversion among injection drug users who shared
syringes (pooled risk ratio = 1.94, 95% confidence inter-
val (CI) 1.53, 2.46) [58], the sharing of syringes is an im-
portant covariate that should be standardized, measured,
and adjusted for in future studies. Although a recent
report by the US Centers for Disease Control (CDC)
suggested that NEPs can reduce the sharing of syringes,
White PWIDs, who are largely driving the HCV epi-
demic in nonurban areas, had the highest rate of syringe
sharing [59].
Importantly, merely providing clean needles to PWIDs
may not be enough to prevent new cases of HCV. Crofts
et al. [60] first documented new HCV infections in
PWIDs who reported no needle sharing, which suggests
that HCV infection could be spread in other ways, such
as sharing of contaminated equipment (e.g., mixing spoons
and filters). Furthermore, a recent study conducted with
heroin injectors in Denver, Colorado, observed barriers to
using a clean needle for every injection, such as being in
withdraw and fear of arrest that may prevent the use of a
clean needle for every injection [61]. However, research
examining these barriers in rural settings is nonexistent
and represents an area ripe for inquiry.
Given the mixed findings and substantial heterogeneity
and inconsistency observed in both this review and pre-
vious reviews, there is insufficient empirical evidence to
either recommend or discount NEP for the prevention
of HCV. However, despite this mixed evidence, the US
CDC recently recommended implementation of these
programs in rural areas that have been disproportion-
ately affected by the recent opioid and heroin epidemics
[59]. Unfortunately, not much is currently known re-
garding the experience of opening these programs in
rural areas. Therefore, research elucidating the unique
context in which these programs are implemented in rural
areas, as well as the challenges and barriers experienced,
is needed. To the best of our knowledge, there are cur-
rently only nine programs listed in the North American
Syringe Exchange Network that are located in Central
Appalachia (two programs in Kentucky, one in Tennessee,
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none in Virginia, and six in West Virginia) [62]. However,
this total represents eight additional programs that have
opened since June, 2014, when only one program operated
in Nashville Tennessee [63].
Strengths
There are at least six potential strengths of the current
meta-analysis. First, to the best of the author’s know-
ledge, this systematic review with meta-analysis repre-
sents the first work using meta-analytic methods to
provide quantitative estimates of the impact of NEPs on
the prevention of HCV in PWIDs since the work of
Hagan et al. [12]. The recently published systematic
review with meta-analysis by Sawangjit et al. [23] only
focused on pharmacy-based NEP and HCV prevalence
(as opposed to the prevention of incident cases). Secondly,
included studies were limited to designs which promote
drawing causal inferences (i.e., cohort and case–control).
Third, studies were not limited to the injection of illegal
drugs. Fourth, these mixed results are consistent with pre-
vious studies. Fifth, the use of an objective serological
measure of the outcome minimized potential bias in the
reporting of HCV status. Sixth, this review has led to
specific recommendations for the design of studies to
minimize between-study heterogeneity and inconsistency,
which may be preventing definitive conclusions regarding
the effect of NEPs on the prevention of HCV.
Limitations
There are at least six potential limitations to be considered
when reviewing the results of this meta-analysis. First, the
current study excluded SIFs and pharmacies from the
search due to our objective of examining the evidence
related to programs that both collect and distribute (i.e.,
exchange) needles. In contrast, SIFs primarily provide
clean needles for the injection of drugs on-site under
medical monitoring. However, it has been noted that SIFs
may have an important role in preventing HCV infection
among PWIDs by serving as an additional mechanism for
the provision of sterile needles in addition to NEPs [64].
Therefore, our results are limited to only one mechanism
of sterile needle access. In addition to sterile needle
provision, SIFs may greatly reduce risky injection practices
(i.e., syringe sharing) that lead to HCV infection [64]. Un-
fortunately, SIFs are not yet widely available in the USA,
in general, and in the rural areas of the USA that are in
the midst of the HCV epidemic, in specific. The very first
SIFs in the USA are preparing to open in 2017 in an urban
location on the West Coast of the USA [65]. Current evi-
dence regarding their impact on HCV seroconversion is
lacking. Hagan et al. [12], upon which we based our search
strategy, failed to find any articles describing the impact of
SIFs or pharmacy sales on HCV seroconversion that met
their inclusion criteria for their systematic review with
meta-analysis. There were 15 studies among the 555 in-
cluded in this systematic review that described SIFs. Only
two of these studies obtained an objective measure (i.e.,
serum or saliva) of HCV infection. However, both studies
were cross-sectional and did not provide data that would
allow calculation of the association between SIF use and
HCV infection. Similarly, and as discussed above, there is
very limited evidence (N = 2 studies) that currently exists
on the impact of pharmacy-based NEP, an area ripe for
further inquiry. Secondly, the current review was unable
to formally assess differential study effects stemming from
different designs using moderator analysis due to the small
sample size. Third, the weaknesses and potential biases in-
herent in individual studies are included in a meta-
analysis, which may have negatively affected this study’s
ability to detect significant results. Such biases include in-
formation bias that could have been present from self-
reports of injection status and NEP attendance, as well as
volunteer bias [66, 67], which represents the phenomenon
of NEP attendance by PWIDs that may be at higher risk
for infectious disease. Fourth, it is possible that studies
were missed during the systematic review and not in-
cluded in the meta-analysis. In addition to not searching
for unpublished sources, the fact that over 100 full text ar-
ticles had to be reviewed to assess inclusion and exclusion
criteria may indicate that studies that address this topic
are not well described in either the title or abstract. Fifth,
a small number of included studies precluded a complete
assessment of the possibility of small study effects, includ-
ing publication bias. Finally, because the aggregate data
approach for this meta-analysis was used, these results are
subject to ecological fallacy [68].
Conclusions
The impact of NEP on the prevention of HCV in PWIDs
remains unclear. Such lack of clarity is likely due to sub-
stantial between-study heterogeneity in study design, inclu-
sion criteria, intervention definition, outcome assessment,
and statistical analyses that yield different pooled results
depending on whether or not a time component (hazard
ratio) is included in the analysis. Studies examining the op-
eration of NEPs in rural areas are particularly needed, along
with research examining the unique barriers to using clean
needles experienced by PWIDs, to clarify the overall contri-
bution of the presence of clean needles in the environment
obtained from NEPs to the successful prevention of new
cases of HCV. Future studies should also examine the im-
pact of other sources of clean needles available for injection,
such as SIFs and pharmacies, on the prevention of HCV
infection in PWIDs. Given the potential benefits of NEP for
reducing infectious disease in a population, future studies
incorporating standardized populations, interventions,
comparisons, outcomes, and analyses are critically
needed to inform public health practice and policy.
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